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yoga vs. educational film program for the
management of restless legs syndrome
(RLS): study protocol for a randomized
controlled trial
Terry Kit Selfe1* , Sijin Wen2, Karen Sherman3, Maryanna Klatt4 and Kim E. Innes5

Abstract
Background: Restless legs syndrome (RLS) is a common and burdensome sleep disorder associated with profound
impairment of health, well-being, and quality of life. Unfortunately, the medications used for RLS management carry
risk of serious side effects, including augmentation of symptoms. Yoga, an ancient mind-body discipline designed
to promote physical, emotional, and mental well-being, may offer a viable, low-risk new treatment. The primary
objectives of this pilot, parallel-arm, randomized controlled trial (RCT) are to assess the acceptability and feasibility
of a 12-week yoga vs. educational film program for the management of RLS.
Methods: Forty-four adults with confirmed moderate to severe RLS will be recruited and randomized to a 12-week
yoga (n = 22) or standardized educational film program (N = 22). Yoga group participants will attend two 75-min
Iyengar yoga classes per week for the first 4 weeks, then one 75-min class per week for the remaining 8 weeks, and
will complete a 30-min homework routine on non-class days. Educational film group participants will attend one
75-min class per week for 12 weeks and complete a daily RLS treatment log; classes will include information on: RLS
management, including sleep hygiene practices; other sleep disorders; and complementary therapies likely to be of
interest to those participating in a yoga and sleep education study.
Yoga and treatment logs will be collected weekly. Feasibility outcomes will include recruitment, enrollment, and
randomization rates, retention, adherence, and program satisfaction. Program evaluation and yoga-dosing
questionnaires will be collected at week 12; data on exploratory outcomes (e.g., RLS symptom severity (IRLS), sleep
quality (PSQI), mood (POMS, PSS), and health-related quality of life (SF-36)) will be gathered at baseline and week
12.
Discussion: This study will lay the essential groundwork for a planned larger RCT to determine the efficacy of a
yoga program for reducing symptoms and associated burden of RLS. If the findings of the current trial and the
subsequent larger RCTs are positive, this study will also help support a new approach to clinical treatment of this
challenging disorder, help foster improved understanding of RLS etiology, and ultimately contribute to reducing
the individual, societal, and economic burden associated with this condition.
Trial registration: ClinicalTrials.gov, ID: NCT03570515. Retrospectively registered on 1 February 2017.
Keywords: Restless legs syndrome, Yoga, Mind-body therapy, Behavioral intervention, Feasibility, Acceptability,
Sleep, Mood, Quality of life
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Background
Restless legs syndrome (RLS) is a distressing sleep and
sensorimotor disorder characterized by a compelling urge
to move the legs, which is usually accompanied by unpleasant sensations in the legs that begins or worsens during periods of inactivity, is worse at night, and is at least
partially relieved by movement [1]. As detailed in our recent reviews [2, 3], RLS affects up to 29% of US and European adults, with estimated prevalence rates averaging
12% in the general population, and 19.5% in primary care
patients [3]. Up to 65% or more of those affected suffer
moderate to severe symptoms [3]. While increasingly recognized as a disorder of significant clinical and economic
import [3–7], the etiology of RLS remains poorly understood [8–10]. Currently, the primary underlying causes of
RLS are thought to be genetic predisposition, dopaminergic dysfunction, and deficiencies in iron metabolism [8–
14], although these factors have to date offered only a partial explanation [2]. As discussed in our recent papers [2,
3, 15], emerging evidence suggests that autonomic and
hypothalamic-pituitary-adrenal (HPA) axis dysregulation
may also play an important role in RLS pathogenesis and
progression.
RLS is associated with significant sleep disturbance [6,
16, 17], the most common presenting complaint of those
seeking medical care for RLS [18, 19], and is a major
cause of chronic sleep loss [20]. Recent studies suggest
that up to 40% of those with insomnia suffer from
RLS [21, 22]. Likewise, mood disturbance is common
in those affected by RLS [16, 23], and can both result
from, and contribute to, sleep deficits [24]. Recent
community-based studies suggest that RLS may also
be linked, in a bidirectional manner, to cardiovascular
disease (CVD), stroke, and key components of the
metabolic syndrome [2, 8, 9, 25], associations that may
be in part mediated by RLS’s adverse effects on sleep
and mood [26, 27]. RLS leads to significant impairment of daily functioning and quality of life, increased
health-related costs, and declines in productivity that are
comparable to those reported in other serious chronic
disorders, including diabetes, hypertension, Parkinson’s
disease, and stroke [6, 7, 26, 28, 29]. Collectively, these
studies suggest that RLS is a serious, chronic condition of
major public health import, affecting a large percentage of
the adult population and exacting a significant toll in
terms of health, quality of life and economic cost.
There is no cure for RLS, with current treatments
aimed at symptom management. Pharmaceuticals, notably dopaminergic agents and anti-seizure medications
(α2δ ligands) remain first-line treatments for RLS, with
opioids and, less commonly, benzodiazepines, used as
second-line therapies [25, 26, 30–32]. Unfortunately, all
medications used for RLS management carry risk of
serious side effects (with 6–80% of patients affected,
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depending on the medication and duration of treatment)
[26, 31, 33]. Among the most troubling is augmentation
of symptoms, a serious clinical problem which has
been reported for all dopaminergic drugs and certain
opioids, with risk increasing with longer treatment
duration [25, 26, 30, 31, 34]. For example, in a recent
community-based study of 266 RLS patients who had
been treated with dopaminergic agents, only 25% had no
evidence of augmentation [35]. Other common side
effects include somnolence and general toxicity (all RLS
medications); impulse control disorders (dopaminereceptor agonists); dyskinesias (dopaminergic agents),
nausea and vomiting (dopaminergic agents, opioids);
mood disturbances (α2δ ligands, opioids, benzodiazepines); weight gain (α2δ ligands); addiction (opioids,
benzodiazepines); increased risk for falls (opioids,
benzodiazepines), and other adverse sequelae [25, 26,
30, 31, 34, 36–44]. In addition, these effects can be
particularly problematic in older adults [45, 46], who
suffer disproportionately from RLS [42, 47]. In addition,
the efficacy of all RLS medications commonly diminishes
with time [31, 48–51], leaving patients with few treatment
options. Given these drawbacks, investigation of safe, sustainable, nonpharmacologic therapies, that may not only
alleviate RLS symptoms, but address associated comorbidities and apparent risk factors, is clearly warranted.
However, despite current clinical guidelines, including
recent recommendations from the International RLS
Study Group Task Force that medications be used only
to treat “clinically significant symptoms that cannot be
effectively managed behaviorally” [31], behavioral treatments remain largely untested and rarely implemented
in practice. Specifically, although lifestyle changes and
relaxation therapies, including yoga, are recommended
for those suffering RLS [10], rigorous supporting research is lacking. To our knowledge, aside from our pilot
studies [15, 52] only three small published trials have
examined the potential benefits of lifestyle/behavioral
interventions for individuals with RLS. These include a
pre-post trial of cognitive behavioral therapy in 25
adults with primary RLS and psychosocial impairment,
and two studies evaluating the effects of a 12–16-week
exercise program vs. usual care on RLS symptoms: a
non-randomized controlled trial in 14 hemodialysis
patients [53] and a randomized controlled trial (RCT)
of 23 community-dwelling older adults [54]. All reported
significant improvement in RLS symptoms among participants assigned to the active intervention vs. the control
group [53, 54] or baseline [55], suggesting that behavioral
therapies may benefit those with RLS.
Study rationale

Supported by our strong preliminary findings, drawing
on the strengths of multiple disciplines, and testing a
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novel, clinical treatment paradigm, the proposed study
will be the first RCT to rigorously assess the feasibility
and acceptability of a promising mind-body therapy
(yoga) for alleviating RLS symptoms and symptom burden. The study will provide essential preliminary data
for a larger RCT to assess the efficacy of yoga for RLS
management, and to evaluate the long-term effects of
this novel therapy. Most important, this study will, in
providing the foundation for the first rigorous trial of a
novel behavioral therapy for RLS, have the potential to
significantly alter the clinical management of this common and burdensome disorder.
As detailed above, medications used in RLS management carry risk of serious side effects that are especially
problematic for older adults, and are often inappropriate
for long-term use. Clearly, there is a need to investigate
potentially safer, sustainable, low-cost therapies that are
suitable for long-term use, and that have the potential
not only to attenuate RLS symptoms, but to address the
common comorbidities that may both result from, and
contribute to, RLS. Particularly urgent is the investigation of promising patient-centered therapies that may
enable and encourage patients to effectively manage
their own health. While current guidelines indicate that
behavioral management should comprise first-line treatment for RLS, and yoga and other relaxation therapies
are sometimes recommended to RLS patients [56], rigorous supportive research is lacking. Findings from our
two small, proof-of-concept studies suggest that yoga
may significantly reduce RLS symptoms, improve sleep,
and enhance mood, and decrease blood pressure in
adults with RLS; observed effect sizes in these small
trials were similar or superior to those reported in RLS
drug trials [57–63], suggesting that yoga may offer a
viable, multi-faceted, low-cost new treatment that is
safer and more suitable for long-term use, and that has
the potential to address symptoms as well as contributing factors.
An ancient mind-body discipline designed to promote
physical, emotional, and mental well-being [64], yoga
continues to gain popularity in the US, with over 13 million Americans reporting use of yoga in 2007 [65]. Our
recent exploratory studies suggest that yoga may attenuate RLS symptoms, improve sleep, enhance mood, decrease stress, and reduce sympathetic activation in
adults with RLS [15, 66], with observed effect sizes
similar to, or greater than, those reported in trials of
established drug treatments [57–63]. Numerous studies
have shown yoga to improve quality of life, enhance
well-being, and reduce pain, outcomes of clear relevance
to RLS sufferers [67–75]. In addition, evidence from
controlled trials by our group and others suggest that
yoga may also improve indices of metabolic and autonomic function linked to both RLS and CVD risk [2, 9,
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76–80]. Yoga has logistical advantages as well. Typically,
a gentle practice with no appreciable side effects, yoga is
relatively simple to learn and inexpensive to implement,
and can be safely performed by a broad range of populations, including chronically ill, elderly, and even disabled
adults [81–86]. The practice of yoga often brings immediate positive benefits, including feelings of relaxation
and tranquility, helping to encourage continued adherence [77]. However, despite the promise of yoga as a
safe, sustainable, cost-effective treatment for RLS, rigorous controlled studies are lacking.
Design

This study will be a pilot, parallel-arm, community-based,
RCT to assess the feasibility and acceptability of a
12-week yoga program vs. a 12-week educational film
program for the management of RLS in adults aged
≥ 18 years with confirmed moderate to severe RLS.
The protocol addresses the elements described in the
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (Additional file 1).
Objectives
Primary objective

Our primary goal is to assess the acceptability and feasibility of a 12-week yoga vs. educational film program for
RLS management in adults with moderate to severe
RLS. Primary aims are as follows:
Aim.1a. Assess participant recruitment and enrollment
rates and determine optimal recruitment strategies.
Reasons for refusal will be recorded and the
information used to develop and implement strategies
to address these barriers where appropriate
Aim.1b. Determine participant retention rates and
adherence in the yoga and educational film groups, with
80% retention, 80% class attendance, 75% home practice
(yoga group), and 80% completion of weekly logs serving
as benchmarks for acceptability. Information on barriers
to adherence will be collected and used to inform
ongoing strategies to enhance compliance
Secondary objectives

Our secondary objectives include the assessment of
treatment fidelity in the two programs, as well as participant willingness to enroll in yoga programs of varying
duration and intensity. In addition, we will measure
RLS symptom severity, sleep quality, mood, and
health-related quality of life at baseline and 12 weeks
to obtain effect size estimates for these exploratory outcomes. This information will provide critical data on
which to base our planned larger RCT to determine the
efficacy of yoga as a potential therapy for RLS. Secondary
aims are as follows:
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Aim.2.1. Monitor and assess treatment fidelity in the
yoga and educational film programs, using specific
metrics to gauge fidelity. Lapses in fidelity will be
recorded and the data used to inform strategies to
address these lapses
Aim.2.2. Assess the effect sizes at week 12 of a beginner
yoga and a structured educational film program for
RLS symptoms and related key exploratory outcomes
(sleep quality, mood, perceived stress, and healthrelated quality of life) in adults with moderate to severe
RLS, using well-validated, self-report instruments
commonly employed in evaluating RLS treatments.
Effect size estimates for these exploratory outcomes
will provide critical data on which to base sample sizes
in future larger trials, as well as provide important
preliminary information on sensitivity of specific
endpoints to change with a 12-week yoga intervention
Aim.2.3. Determine acceptable doses of yoga for a trial
by assessing participant willingness to complete, as well
as preference for yoga programs of the following

Fig. 1 Study flow diagram
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duration and intensity: 8 weeks, 16 classes (2x/week);
12 weeks, 16 classes (2x/week for first 4 weeks, 1x/week
thereafter); 16 weeks, 16 classes (1x/week).
Acceptability and preferences will be evaluated using a
self-report questionnaire administered to all participants at the follow-up assessment visit

Methods
Participants

Forty-four ambulatory, overall healthy adults aged ≥ 18
years with confirmed moderate to severe RLS will be
recruited and randomized to a 12-week beginner yoga
program (n = 22) or a standardized 12-week educational
film program (N = 22), modeled on interventions used
in our previous trials [15, 87] (see Fig. 1).
Inclusion criteria

Study participants will be ambulatory adults ≥ 1 years of
age with moderate-severe RLS, defined as:
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1. Symptoms that meet all five of the International
RLS Study Group’s essential diagnostic criteria for
RLS [1, 88] (i.e., (1) an urge to move the legs, often
associated with discomfort or disagreeable
sensations in the legs, that (2) begins or worsen
during periods of rest or inactivity; (3) is partially or
totally relieved by movement; (4) is worse or only
occurs in the evening or night; and (5) is not solely
accounted for by another condition (e.g., leg cramps,
positional discomfort, habitual foot-tapping))
2. RLS symptoms at least 1x/week for the previous 3
months
3. A score of at least 2 points (moderate) IRLS
question 6: “How severe was your RLS as a whole?”
[89, 90]; and
4. Confirmation of RLS diagnosis and study eligibility
by a physician trained in sleep medicine; these
criteria will help ensure exclusion of mimics
(e.g., leg cramps, positional discomfort, arthritis
pain, etc.) [20, 91]. Additional criteria include:
willingness and ability to complete the 12-week
yoga or educational film program and all study
assessments; and willingness to avoid use of any
new drugs or treatments other than the assigned
intervention.
Exclusion criteria

Exclusion criteria are as follows: practiced yoga within
the past year; currently on anti-psychotic medication;
changed dosage of dopaminergic agents (e.g., levodopa,
ropinirole, pramipexole) or any other central nervous
system agents (e.g., sedative hypnotics, GABA analogs,
narcotic analgesics, antiadrenergic agents, or anticonvulsants) within the past 3 months; hemoglobin (Hb) < 12
g/dL for women,< 13 g/dL for men; any orthopedic,
neurologic, or other condition that might prevent safe
completion of a 12-week yoga program or confound assessments (e.g., neuropathy; Parkinson’s disease; stroke;
rheumatoid arthritis; renal failure; sleep apnea; recent
(within the last 6 months) myocardial infarction; heart
failure; cancer (other than non-melanoma skin cancer);
pregnancy, or within 6 months post-partum). These
medical exclusion criteria are consistent with those commonly employed in trials of RLS drugs and other RLS
interventions [54, 92–96].
Sample size

We performed a simulation study to determine the total
sample size required to derive precise estimates of effect
sizes for a two-arm randomized trial using a 1:1
randomization scheme for the primary intervention
(yoga) and the educational film program; estimates were
based on regression models using multiple simulations and
scenarios, and specifically accounting for heterogeneity of
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effects. We considered seven combinations of effect sizes
at 23 different sample sizes for total of 161 effect and
sample size combinations. For each combination we ran
5000 simulations for a total of 805,500 simulations. The
seven effect-size combinations were structured under the
conservative assumption that all interventions would lead
to a small to moderate improvement in outcomes and that
the yoga intervention would lead to an improvement equal
to or greater than the comparator condition. We used repeated simulations to determine the required post-attrition
total sample size needed to obtain precise estimates of all
three treatment effects under an intent-to-treat (ITT) analysis of variance (ANOVA) analysis. Based on findings of
the simulation study and assuming 20% attrition, a sample
size of 44 participants will permit reasonably precise estimates (within 95% confidence intervals of the true effect
size value) for the two interventions, as well as reasonable
estimates of recruitment, randomization, and adherence
rates; moreover, estimates remain robust even at 30%
attrition. Thus, the study will be adequately powered even
if effect sizes for the yoga program are substantially smaller,
and attrition rates greater than observed in our pilot
studies [15, 66].
Recruitment and study setting

Participants will be recruited from two sites: Morgantown, WV metropolitan area (WVU site) and Columbus,
Ohio (The Ohio State University (OSU) site). In the
WVU site, we will mail recruitment letters to all patients
visiting a Morgantown area University Health Associates
(UHA) clinic, who received a diagnosis of RLS (ICD-9
code: 333.94, 333.99) during the 5 years preceding study
onset, as identified by electronic visit data. Consistent
with Institutional Review Board (IRB) and Health Insurance Portability and Accountability Act (HIPAA) guidelines, the mailing list was obtained based on IRB approval
of a waiver of research participants’ authorization for the
use/disclosure of information. Only the minimum necessary information needed to identify potentially eligible
subjects was accessed (i.e., name and mailing address).
At both sites, we are recruiting from the community
using local television, radio, and print media advertisements, as well as flyers and brochures posted in public
places such as community bulletin boards (physical
and electronic); health center waiting areas, and intranets.
Study staff will also give presentations regarding the trial
to interested lay and professional groups in the area,
including clinician, support, university extension, and
church groups, as well as other regional organizations
and conferences. These strategies have proved effective in
recruiting participants for previous studies of yoga-based
interventions by WVU investigators in Morgantown, WV
and by our partner investigators at OSU in Columbus,
OH [52, 97–102].
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Prospective study participants are being invited to
contact the WVU study coordinator for further information. A member of the investigative team will describe
the study, including eligibility criteria, to each potential
participant over the telephone; those still interested will
then be scheduled for a screening interview and baseline
assessment, and sent a copy of the consent form to preview at their leisure prior to their first appointment.
Consent and screening

We plan to enroll a minimum of 15 participants for each
study cohort; within each cohort, participants will
complete their baseline and follow-up assessments
within the same 30-day window, and those in the yoga
and film groups will begin and complete their respective
classes at the same time. All class schedules will be fixed
prior to randomization; as in our previous trials, every
effort will be made to accommodate participant availability and preferences with respect to class timing.
At visit 1, an investigator will review the informed
consent form with each participant in a private room; individuals still interested in participating in the study will
sign the consent form. Each participant will sign two
copies of the consent form, one to be given to the participant, and one to be stored with the study documents
in a locked cabinet in a secure room in the WVU School
of Public Health. Participant eligibility will be assessed
using the IRLS (question 6) [89, 90] and a standardized
screening checklist, similar to that used in our previous
trials, which covers all of the eligibility criteria.
Hemoglobin (Hb) levels will be assessed noninvasively,
using the Masimo Pronto, a simple, hand-held pulse
oximetry Hb monitor that has demonstrated excellent
reliability and precision in both clinical and healthy
populations [103–106]. Reasons for ineligibility and for
non-participation of eligible candidates will be documented in a screening log.
Screening evaluations will occur within 30 days prior
to the start of the intervention. Participant eligibility will
be assessed using a standardized screening checklist
similar to that used in our previous trials, which covers
the inclusion and exclusion criteria (including RLS diagnostic criteria and at least moderate RLS severity); Hb
levels will be assessed using the Masimo Pronto, a simple, hand-held pulse oximetry Hb monitor that has demonstrated excellent reliability and precision [103–106].
Interventions
Yoga program (active intervention)

Participants randomized to the yoga group will complete
a gentle Iyengar yoga program based on that developed
and successfully implemented in our pilot studies [15,
66]. The yoga program was finalized following detailed
review and input from an Iyengar Master Trainer.
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Program logistics: yoga group participants will attend
two 75-min classes per week for the first 4 weeks, then
one 75-min class for the remaining 8 weeks, and will be
asked to complete a 30-min homework routine 5 days/
week on non-class days. Yoga classes will be held at two
yoga studios in close proximity to the WVU Health
Sciences Center campus (WVU site) and OSU Center
for Integrative Health and Wellness (OSU site), respectively. As in our previous trials [15, 66], each yoga class
will begin with simple yogic centering and breathing exercises, followed by a sequence of active and restorative
poses, and ending with a 10-min guided supine relaxation practice. The yoga routines, including a collective
total of 25 common asanas, have been tailored for
sedentary adults naïve to yoga, gradually increasing in
difficulty as students progress. Pose modifications and
props (e.g., chairs, blankets, and straps) will be used as
needed to enable participants to perform the poses safely
and easily, regardless of their level of physical ability or
fitness. In addition, each class will be restricted to no
more than 12 participants to allow for personalized
attention. The home practice (see Table 1) will be performed with the aid of a yoga DVD and a comprehensive, indexed training manual illustrating the homework
routines; These guides are based on materials developed
for our preliminary trials and modified to reflect the
extension to a 12-week intervention period for the
proposed study. Participants will also be provided yoga
mats and straps to facilitate home practice.
Educational film program (comparator)

Participants assigned to this group will attend one 75
min class per week for 12 weeks, and will be asked to
complete a daily log at home recording any RLS or sleep
treatments they tried based on what they learned in class
or for any other reason. At the first class, film group
participants will receive a comprehensive set of lay educational materials regarding RLS symptoms, causes, and
epidemiology and detailing nonpharmacologic strategies
for RLS management based on current national guidelines, including recommendations regarding sleep hygiene, lifestyle modifications, and behavioral approaches.
Each class will be held at the WVU Health Sciences
Center, and include a brief meet-and-greet period at the
start of class, an instructional film segment of approximately 60 min, and a 10–15-min group discussion, facilitated by a health educator familiar with sleep disorders
and common nonpharmacologic treatments. While
sitting for 75 min/week is unlikely to lead to worsening
of symptoms in this largely sedentary population, we
will, as in our previous trials, encourage participants to
stand and/or stretch during the film and discussion if
they so desire. All participant comments will be noted,
and, together with information provided on the exit
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Table 1 Yoga home practice routines

Table 1 Yoga home practice routines (Continued)

Home Practice 1: Weeks 1–3 (use wall for side-angle standing poses)

heels on wall

Svanasana

1. Upward extended-leg pose

Urdhva Prasarita
Padasana

10. Extended one-foot frog pose

Utthita Eka Pada
Bhekasana

2. Straight-leg pose: (a) bent knee 3x, (b) straight leg 2x

Supta
Padangusthasana

11. Thunderbolt pose

Vajrasana

12. Staff pose

Dandasana

13. Seated wide-angle pose

Upavistha Konasana

14. Bound angle pose (2 blankets)

Baddha Konasana

15. Seated twist pose (in chair)

Bharadvajasana (on
blankets)

16. Supported bridge pose

Setubandha
Sarvangasana

17. Corpse pose

Savasana

18. Corpse pose with breathing

Savasana Pranayama

3. Upward extended arms in mountain pose: (a) palms
forward, (b) palms facing

Urdhva Hastasana in
Tadasana

4. Extended side-angle pose

Utthita
Parsvakonasana

5. Half-intense pose: (a) hands to wall, (b) hands on
chair

Ardha Uttanasana

6. Extended triangle pose

Utthita Trikonasana

7. Extended one-foot frog pose

Utthita Eka Pada
Bhekasana

8. Seated wide-angle pose

Upavistha Konasana

9. Bound-angle pose

Baddha Konasana

10. Seated twist pose (in chair)

Bharadvajasana

11. Corpse pose

Savasana

12. Corpse pose with breathing

Savasana Pranayama

Home Practice 2: Weeks 4–6 (use wall for side angle standing poses)

Home Practice 4: Weeks 10–12 (no wall for side angle standing poses)
1. Upward extended-leg pose

Urdhva Prasarita
Padasana

2. Straight-leg pose: straight leg 1x

Supta
Padangusthasana

3. Fierce pose: feet apart

Utkatasana

4. Extended side-angle pose

Utthita
Parsvakonasana

1. Upward extended-leg pose

Urdhva Prasarita
Padasana

5. Intense pose: holding elbows

Uttanasana

2. Straight-leg pose: straight leg 3x

Supta
Padangusthasana

6. Downward-facing dog pose

Adho Mukha
Svanasana

3. Upward extended arms in mountain pose: palms
facing coming up from the side

Urdhva Hastasana in
Tadasana

7. Warrior I pose: back heel at wall

Virabhadrasana I

Utthita
Parsvakonasana

8. Hero’s pose

Virasana

9. Garland pose: (a) hold elbows, (b) extend arms

Malasana

5. Half-intense pose: hands to the wall

Ardha Uttanasana

10. Bound angle pose

Baddha Konasana

6. Warrior II pose

Virabhadrasana II

11. Head-to-knee pose

Janu Sirsasana

7. Extended triangle pose

Utthita Trikonasana

12. Western intense pose

Paschimottanasana

8. Intense pose: buttocks on the wall and hands on
books

Uttanasana

13. Active bridge pose

Chatush padasana

14. Corpse pose

Savasana

15. Corpse pose with breathing

Savasana Pranayama

4. Extended side-angle pose

9. Extended one-foot frog pose

Utthita Eka Pada
Bhekasana

10. Thunderbolt pose

Vajrasana

11. Seated wide-angle pose

Upavistha Konasana

12. Seated twist pose (in chair) (2 blankets)

Bharadvajasana

13. Supported bridge pose (2 blankets)

Setubandha
Sarvangasana

14. Corpse pose: feet to the wall

Savasana

15. Corpse pose with breathing

Savasana Pranayama

Home Practice 3: Weeks 7–9 (no wall for side angle standing poses)
1. Upward extended-leg pose

Urdhva Prasarita
Padasana

2. Straight-leg pose: straight leg

Supta
Padangusthasana

3. Fierce pose: back to wall

Utkatasana

4. Extended side-angle pose

Utthita
Parsvakonasana

5. Half-intense pose: hands on books

Ardha Uttanasana

6. Warrior II pose

Virabhadrasana II

7. Extended triangle pose

Utthita Trikonasana

8. Intense pose: holding elbows

Uttanasana

9. Downward-facing dog pose: (a) hands at wall, (b)

Adho Mukha

questionnaire, will be used to refine the program for the
larger trial. Upon study completion, film group participants will receive all yoga homework materials, and be
offered a half-day workshop in yoga for RLS.
Course content for this standardized film education
program will include information on: RLS symptoms,
epidemiology, and management, including sleep hygiene
practices; other sleep disorders and associated comorbidities, and on mind-body and other complementary
therapies likely to be of interest to those taking part in a
yoga and sleep education study. As in our previous RCT
[87], educational films comprise the mainstay of the
instructional program, allowing participants to be informed by nationally-recognized subject experts on a
variety of topics in a professional and entertaining way.
This 12-week program is designed to be easily replicable
and to ensure reasonable comparability of staff attention
and social interaction. The film selection procedure was
similar to that successfully employed in our earlier
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studies; 41 commercially available documentary and
educational films were screened for content relevance,
accuracy, and likely appeal to the target study population. Each film was reviewed by three or more members
of the study team, and films for inclusion in the program
were selected by consensus. The program includes 11
films, including three regarding sleep, and one specific
to RLS (see Table 2).
Criteria for discontinuing or modifying allocated
interventions for a given trial participant

Each class will be restricted to no more than 12 participants to allow for personalized attention. In the event
that a participant experiences an adverse event (AE)
which makes continuation of the intervention unsafe for
that individual, the study coordinator will inform the
principal investigator (PI) and the study physician, referencing just the participant’s study ID number, and the
intervention will be discontinued for that participant.
With their permission, participants will continue to be
followed if the study intervention is discontinued. Any
AE requiring discontinuation that is judged to be due to
the intervention will prompt re-evaluation and possible
modification of the intervention.
Strategies to improve adherence to intervention protocols
and procedures for monitoring adherence

Attendance data and homework logs will be collected
each week by the group instructor, and monitored for
non-adherence. Instructors will query non-adherent participants to ascertain reasons for non-adherence and determine appropriate strategies to approve adherence
(e.g., scheduling a different time of day for performing
or recording homework, using yoga props or modified
versions of poses, following the yoga routine from previous weeks if the current routine is too challenging or
problematic, etc.).
Relevant concomitant care and interventions that are
permitted or prohibited during the trial

As noted above, exclusion criteria include the use of
anti-psychotic agents and change in dopaminergic or
other central nervous system agents within the previous
3 months; any change in medication use or dosage during the trial will be monitored. In addition, participants
are asked to avoid the use of any new drugs or treatments other than the assigned intervention, and are not
allowed to participate in another intervention study for
the duration of the trial. No concomitant interventions
are required.
Instructors

All study yoga instructors have been certified in Iyengar
yoga (≥ 500 h), with at least 3 years of experience
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teaching adults with a range of chronic health conditions
and trained in the final RLS yoga protocol by lead study
yoga teacher, Dr. Kimberly Williams. Instruction will be
aided by an illustrated training manual and reference
guide based on our pilot work and provided to each instructor along with the home-practice DVD.
The film intervention will be administered by a health
educator versant in sleep disorders and an advanced
graduate student trained for this purpose. This program,
based predominantly on educational films, is designed to
be easily replicable. The instructor’s role is primarily to
facilitate group discussion of the content presented in
the films.
Assignment of interventions
Allocation and concealment

The statistician, who will have no contact with the participants, generated a randomized assignment master list
and provided sequentially numbered opaque envelopes
containing the group assignment and corresponding
study forms. The consenting team member will assign
the unique number from the next envelope in sequence
as the participant’s study ID, and enter the number and
participant name on a secure electronic database; this
information will be linked to the randomization assignment, with the linked data stored in a separate
password-protected database. The sealed, numbered assignment packet will be given to the participant at the
conclusion of visit 1 after collection of baseline data.
Randomization

Randomization will occur immediately following completion of baseline evaluations and no more than 30 days
prior to initiation of the intervention. Eligible participants will be randomized using a 1:1 ratio, to the yoga
(N = 22) or educational film group (N = 22), based on an
allocation sequence generated by the study statistician
using a randomly varying block randomization method to
ensure equal distribution among treatment groups [107].
Blinding

The majority of study personnel will be blinded to treatment assignment until the database is deidentified and
locked. The randomization scheme will be devised and
provided by an individual with statistical expertise who
has no access to the data or influence on study outcomes; this individual will maintain the master coding
sheet indicating the treatment assignment corresponding
to each participant number. Following confirmation of
eligibility and baseline assessment, randomization will be
performed by the consenting team member, who will
have no advance knowledge of treatment allocation;
sealed, opaque envelopes containing information regarding the participant’s assigned intervention will simply be
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Table 2 Educational film program
Special section or timing cues
Session 1
Introduction to the study and distribution of restless legs syndrome (RLS)
information packets
Restless Leg Syndrome: An Uncontrollable Urge to Move (2012)
(Part of the award-winning series: Healthy Body, Healthy Mind)
Good Night with the Sleep Doctor DVD (2008) (Dr. Michael Breus)

Act 1 [end at 25:15]

Session 2
Good Night with the Sleep Doctor DVD (2008) (Dr. Michael Breus)

Acts 2 and 3

Session 3
10 Things You Should Know About Sleep (2009) (A BBC production)
Session 4
The New Medicine (2006) (FREDDIE award winner for excellence in
health and wellness media)

Part 1 [3:37–56:30]

Session 5
Mindfulness and Meditation: Stress Reduction (2000) (Jon Kabat-Zinn)
Session 6
Stress and Relaxation Explained: An Introduction to Stress Management
and Relaxation Techniques (2007)

Introduction;
Part 1 (Stress): Explanations: Nature of Stress,
Biological Origins, Symptoms, Health Effects;
Part 2 (Relaxation): Relaxation Techniques:
Mind-Body Medicine, Managing \Stress,
Relaxation Techniques; Real World Balance;
Part 4 (Guided relaxation)

Session 7
Yoga Unveiled: The Evolution and Essence of a Spiritual Tradition (2004)

Part 5: Yoga as Therapy

Session 8
UCSF’s Mini Medical School for the Public – Health and Vitality: What
Science Tells Us About How to Thrive (2011)
Session 9
The Connection (2014)

Main section

Session 10
Happiness 101 with Tal Ben-Shahar (2009)

Main section

Session 11
The Real Age Makeover with Michael F. Roizen, MD (2005)

Part I

Session 12
The Real Age Makeover with Michael F. Roizen, MD

Q&A [to 24:08]

Happiness 101

Sloat bonus material

The Connection

Benson Interview

uniquely numbered, with no external indication of treatment assignment; as in previous studies, participants will
be instructed to open their envelopes upon exiting the
building. The study coordinator will maintain the list
linking participant numbers with personally identifiable
information. Assessments will likewise be conducted by
trained study personnel blinded to treatment allocation
and specifically hired for this purpose. The yoga and
educational film group instructors will be responsible for
documenting attendance and collecting homework logs,

as well as for contacting participants. Instructors will
not have access to the data or be involved in data monitoring or analysis. Data will be entered (double-keyed)
into an existing data template by two students trained in
data management; participants will be identified only
using a unique number.
In the unlikely event that there are three serious adverse events (SAEs) in either group that are judged to be
related to the intervention, the study coordinator will inform the PI of this fact. Up to this point, the PI will be
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aware of all SAEs but will be unaware of the affected
participant’s group assignment. If the PI agrees that the
SAEs are related to the intervention, she will determine
that the blind will be broken. In that event, the study coordinator will give the list linking participant numbers
with personally identifiable information to the PI.
Data collection and outcomes

Assessments will be conducted by study team members
with training and experience in clinical assessment; all
assessment personnel will be blinded to treatment assignment. Baseline data, including that on exploratory
outcomes, will be collected prior to randomization (see
“Patient timeline” below).
To determine feasibility and acceptability of the
12-week yoga and educational film comparator program,
our primary aim, we will collect comprehensive information, both overall and by treatment group, on: rates of
recruitment and success of different recruitment strategies, and reasons for refusal to participate; screening,
randomization and enrollment rates, including reasons
for screening failures and refusals to enroll/be randomized to treatment; rates of retention (completion of assessment visits) and adherence (completion of home
logs and class attendance rates (yoga and film groups);
completion of home practice (yoga group)); and participant satisfaction, assessed via a structured program
evaluation questionnaire regarding participant perceptions of, and experiences with, the study and their respective programs. Attendance data will be collected by
the instructor for each group, as will homework logs.
Participants will complete the program evaluation questionnaire, modeled on that used in our previous trials
[15, 87, 108], upon completion of the 12-week intervention period or upon leaving the study.
A structured questionnaire regarding possible
yoga-dosing scenarios will be administered at week 12 to
determine participant preferences relative to yoga programs of varying duration and intensity (8 weeks, 16
classes (2x/week); 12 weeks, 16 classes (2x/week for the
first 4 weeks, 1x/week thereafter); 16 weeks, 16 classes
(1x/week), as well as time of year that the classes meet.
Information from this questionnaire will address a secondary aim, and aid in optimizing the yoga protocol for
our future studies.
Data on exploratory outcomes and certain modifying/
confounding factors will be collected at baseline and 12
weeks to determine the effect sizes of the programs, data
critical to the design of the planned larger RCT. RLS
symptom severity, the primary efficacy outcome for the
full-scale trial, will be evaluated using the International
RLS Rating Scale (IRLS), a 10-item scale which includes
questions related to frequency, intensity, and impact
[89]. Considered the gold standard for measuring RLS
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symptoms [109, 110], this instrument is recommended
for use in RLS clinical trials by the European RLS Study
Group (EURLSSG) [111], and is widely used both in the
US and internationally [3, 112]. Additional exploratory
outcomes are sleep quality, mood, and health-related
quality of life (HrQOL), endpoints recommended for inclusion in all clinical trials of RLS [26, 111]. These outcomes will be assessed via a short battery of self-report
instruments commonly used in pharmaceutical trials of
RLS patients [113–116]. Sleep quality will be assessed
using the nine-item Pittsburgh Sleep Quality Index
(PSQI) [117]; mood will be evaluated using the 65-item
Profile of Mood States (POMS) [118] and 10-item
Perceived Stress Scale (PSS) [119, 120]; and HrQOL will
be measured using the 36-item MOS Short Form-36
(SF-36) [121, 122]. These self-report instruments are
well-established scales that have been shown to be sensitive to short-term behavioral interventions, and have
been validated in a wide range of populations, including
RLS patients [118, 123–137]. As in our previous trials
[15, 66] we will also assess potential changes in blood
pressure and heart rate to determine effect sizes in these
indices of sympathetic activation; heart rate and blood
pressure will be measured three times at each assessment using an automated blood pressure monitor
(Omron HEM-780) after a 5-min seated rest period.
To measure change in social support and physical
activity, potential modifying or confounding variables,
participants will complete the 11-item Duke Social Support Index (abbreviated form [138, 139]) and 10-item
Physical Activity Scale for the Elderly [140–142] (to
capture physical activity other than yoga) at each visit;
information on Body Mass Index (BMI, calculated as
weight(kg)/height(m)2), caffeine and alcohol consumption, smoking, and use of non-RLS medications will also
be collected at each assessment. To assess expectation of
benefit, the Credibility/Expectancy Questionnaire (CEQ)
[143, 144] will be collected from participants after their
first class. Participants will be asked to record use of
other RLS treatments on their weekly logs.
Patient timeline (Fig. 2)
Data management

Completed data forms or other hard-copy documents
containing protected health information will be kept in a
locked file in an investigator’s office. Data will be entered
into an electronic deidentified database by authorized
study team members, checked for completeness and accuracy. The PI or study staff will review all data collection
forms on an ongoing basis for data completeness and
accuracy as well as protocol compliance. Access to data
with identifiers will be restricted to authorized study team
members and regulatory authorities. Data verification will
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Fig. 2 Schedule of evaluations. *To be monitored continuously throughout study until study is closed to enrollment. Abbreviations: BP blood
pressure, BMI Body Mass Index (weight(kg)/height(m)2), CEQ Credibility/Expectancy Questionnaire, HR heart rate, DSSI Duke Social Support Index,
IRLS International Restless Legs Scale, PASE Physical Activity Scale for the Elderly, POMS Profile of Mood States, PSQI Pittsburgh Sleep Quality Index,
PSS Perceived Stress Scale, SF-36 36-item MOS Short Form-36, Tx treatment

be performed by someone other than the individual
originally collecting the data, or by double-data entry.
Electronic data will be stored on a secure server which
is maintained, with regular back-ups, by WVU Health
Sciences Center system administrators and accessible from
password-protected computers in the WVU Department
of Epidemiology. Any data, forms, and other records with
identifiers that leave the site will be transported in a
locked file box to maintain confidentiality. Identifiable
data will be destroyed 5 years after study completion or 3
years after the last publication based on when the data is
published, whichever comes last (unless future regulations
dictate that the data be kept for longer).
Statistical methods

All analyses will be performed using SAS [145] or R [146].
For the primary feasibility aims, we will be evaluating
recruitment and enrollment rates (all interested potential
participants), acceptability of randomization (all enrolled
subjects), retention, and adherence (all randomized participants). For the secondary aims, we will define the

intent-to-treat (ITT) population as all subjects who are
randomized with baseline assessments and at least one
post-randomization assessment. The per-protocol analysis
of the exploratory outcomes (RLS symptoms, sleep quality, mood, stress, and quality of life) will include all participants who completed both assessments and at least 75%
of the classes.
Feasibility of the proposed design (A.1) will be evaluated in several ways:
Recruitment: we will examine recruitment time and
success rates for different recruitment strategies and
assess the percentage of interested volunteers who meet
the study criteria, agree to participate and are randomized.
We will use Fisher’s exact test to determine whether there
are any differences in recruitment rates across the different strategies, and exponential regression model to assess
the recruitment strategy on recruitment time.
Retention: will initially be assessed using descriptive
statistics, including comparisons between retained individuals and drop-outs. The nonparametric Kaplan-Meier
curve will be used to estimate the probability of
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retention over the duration of the study. If retention is
unexpectedly low, we will use the proportional hazard
model to assess retention differentials by treatment,
demographic, and health-related factors to better target
and retain specific groups in future trials.
Randomization success: (i.e., the two groups are similar
demographically and on anthropometric and exploratory
outcome measures at baseline) will be assessed using the
one-sample run test. To evaluate adherence to the study
protocol, we will determine missing-data rates at baseline
and follow-up, class attendance (both groups), and completion of weekly logs.
Treatment fidelity (A.2.1) will be monitored and lapses
recorded and compared between groups, along with outcomes of remediation strategies. We will use the Fisher’s
exact (continuous data) and chi-square tests (using
benchmark cut-offs) to determine potential differences
in treatment adherence and fidelity.
Treatment effect sizes (A.2.2), based on between-group
differences in change over time, will be estimated using
one-way ANOVA models. Effect size estimates will be
calculated using both ITT (primary) and per-protocol
analyses. These unbiased estimates of intervention effect
size will inform sample size determination for our
planned future efficacy trial [147]. Scores on the
Yoga-dosing Questionnaire (A.2.3) will also be assessed
using descriptive statistics to determine optimal scheduling and maximum acceptable dosing of yoga for our
future trial.
Missing data: every effort will be made to minimize
missing data relevant to all aims. If missing data does
occur and the missing-data pattern (probability model)
is not missing completely at random (MCAR), then we
will consider approaches appropriate for missing at
random (MAR) and missing not at random (MNAR). If
the pattern or structure of the plausible missing data
suggests MAR, either the EM algorithm [148], inverse
weighting [149], or multiple imputation (MI) [150, 151]
will be used and the missing-data mechanism will be
constructed from the collected data [150, 152, 153]. The
selected method will reflect the appropriateness of the
method to best estimate the underlying missing-data
mechanism [148–150, 152]. Participant characteristics
will be assessed, including demographic and lifestyle characteristics, RLS severity, medical history, health-related
factors, and baseline questionnaire scores for the estimation of plausible models (i.e., MCAR, MAR, and MNAR)
for the missing-data mechanism. While we will not be
able to definitively test if the missing data are MNAR, If
there are indicators suggestive of MNAR (e.g., drop-outs
differ significantly from non-drop-outs in key characteristics), we will use MI in conjunction with a sensitivity
analysis to provide a set of plausible conclusions recognizing that each conclusion will be predicated on
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the assumptions necessary for constructing a MNAR
missing-data mechanism model [150, 153].
Data monitoring, harms, and auditing

The frequency of data review for this study differs according to the type of data and can be summarized as
follows: data on accrual, status of all enrolled subjects,
adherence, and AEs will be reviewed by the PI and study
coordinator every 4 months; accrual and AEs will also
be reviewed yearly by the PI, IRB, Independent Monitoring Committee (IMC) (comprising three experts with
appropriate expertise and experience in clinical trials,
biostatistics, and clinical medicine), and NCCIH; SAEs
will be reviewed per occurrence by all.
While both programs are minimal risk interventions,
we are further ensuring participant safety by: using
highly trained Iyengar instructors experienced in teaching adults with chronic health conditions and in adapting poses to minimize discomfort and risk of injury;
including only gentle postures in the program; and
maintaining small class sizes to ensure adequate personalized attention. In addition, all participants will be encouraged to report any AEs to study staff and on their
yoga and co-intervention logs. Yoga group participants
will also be queried about AEs by the yoga instructors
during class. Yoga instructors will notify the study coordinator regarding any AE.
The study coordinator will promptly report AEs to the
IRB according to protocol and IRB policies; complete an
adverse events form and grade the AE; and contact the
participant by telephone on a weekly basis to monitor
the event until the event resolves, the study is completed, or the participant is removed from the study. In
addition, subjects can choose to stop the study at any
time. Any serious and unexpected AEs will require
re-evaluation of the risk of the study. Monitoring and
aggregate review will be performed by the PI, IRB, and
IMC through annual review.
Stopping rules

This study will be stopped prior to its completion if: (1)
the intervention is associated with adverse effects that call
into question the safety of the intervention; (2) any new
information becomes available during the trial that necessitates stopping the trial; or (3) other situations occur that
might warrant stopping the trial. Because this RCT is
specifically designed to be a feasibility study, and we will
be investigating recruitment rates and optimal recruitment strategies as part of our primary aim, slow accrual
would not comprise a justification for stopping the trial.
In addition, the study may be discontinued at any time
by the IRB, NCCIH, the OHRP, or other government
agencies as part of their duties to ensure that research
participants are protected.
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Discussion
In summary, RLS is a common and burdensome sleep
disorder associated with profound impairment of health,
well-being, and quality of life, and with significant personal, societal, and economic burden [6, 7, 26]. There is
no cure for RLS, and current front-line drug therapies
can carry severe side effects. If, as our promising preliminary data suggests, yoga ultimately proves feasible and
effective in reducing RLS symptoms and symptom burden, yoga will offer a novel, safe, and likely cost-effective
approach to RLS prevention and management, targeting
not only RLS symptoms, but also likely contributing
factors and common comorbidities.
This study will lay the essential groundwork for a
planned larger RCT to determine the efficacy of a yoga
program for reducing symptoms and the associated burden of RLS, a common and potentially debilitating sleep
disorder. Specifically, central goals of this trial include
evaluating the feasibility and acceptability of a 12-week
RCT of yoga vs. an attention control, and optimizing the
yoga protocol for a planned larger trial of yoga for RLS
management; we will also obtain effect size estimates for
specific outcomes of relevance to RLS management,
information critical to designing and powering our
planned future study. Based on our strong pilot data, the
study is consistent with the urgent national need to curtail spiraling health care costs and to identify sustainable,
potentially cost-effective new approaches to chronic
disease management. If the findings of the current trial
and the subsequent larger RCT are positive, this study
will also help support a new approach to clinical treatment
of this challenging disorder, help foster improved understanding of RLS etiology, and ultimately contribute to
reducing the individual, societal, and economic burden
associated with this condition.
Ethics and dissemination

This study has been approved by the West Virginia
University Institutional Review Board (IRB#1505699758).
No significant changes will be made to this protocol without the prior approval of the WVU IRB and the NCCIH.
As described above, each participant will provide written
informed consent prior to the initiation of baseline assessments or the intervention.
Confidentiality

During this study, medical history, vital signs, and assessment questionnaires will be completed at baseline
and at regular intervals during the study. All of the
material collected are for research purposes only, and
data will be kept in strict confidence. Information will
not be released without written permission of the participant, except as necessary for monitoring by the IRB,
the NCCIH, the OHRP, and the IMC. Confidentiality
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will be ensured by use of identification codes. This data,
collected at the assessment visits, will be identified with
a study identification code unique to the subject.
Dissemination plans

Upon completion of the trial, the authors plan to present
the study findings at conferences aimed at physicians
typically treating patients with RLS, and at other integrative
health care practitioners such as yoga therapists. In
addition, the investigators plan to submit our findings for
publication in relevant peer-reviewed journals; we do not
intend to hire professional writers.

Trial status
This trial is currently open for enrollment.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist. (DOC 123 kb)
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